Relationship between adhesion molecules and virological response to pegylated interferon-alpha-2a treatment in patients with chronic hepatitis B: A pilot study
Article first published online: 8 JAN 2014
© 2013 Research Department, The First Affiliated Hospital of Chongqing Medical University. Hepatology Research © 2013 The Japan Society of Hepatology
Volume 44, Issue 12, pages 1172–1178, November 2014
How to Cite
Gong, X., Qin, B. and Ma, Q. (2014), Relationship between adhesion molecules and virological response to pegylated interferon-alpha-2a treatment in patients with chronic hepatitis B: A pilot study. Hepatology Research, 44: 1172–1178. doi: 10.1111/hepr.12251
- Issue published online: 20 OCT 2014
- Article first published online: 8 JAN 2014
- Accepted manuscript online: 3 OCT 2013 09:35AM EST
- Manuscript Accepted: 24 SEP 2013
- Manuscript Revised: 6 SEP 2013
- Manuscript Received: 22 JAN 2013
- National Natural Science Foundation of China. Grant Number: 81271838
- Natural Science Foundation of Chongqing city (CSTC). Grant Number: 2008BB5079
- Key program of Chongqing Health Bureau. Grant Number: 2011-1-040
- adhesion molecule;
- chronic B hepatitis;
- pegylated interferon-alpha-2a
We performed a clinical study to investigate potential association between serum levels of soluble adhesion molecules and virological response to pegylated interferon-alpha-2a (PEG IFN-α-2a) treatment in patients with chronic hepatitis B (CHB).
Thirty-two patients with chronic hepatitis B virus genotype B were recruited in this study, who were treated with PEG IFN-α-2a 180 μg every week and then followed up for 24 weeks. Thirty healthy control subjects were recruited from volunteer blood donors. Serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), soluble L-selectin (sL-selectin) in patients were investigated by enzyme-linked immunoassay before and after treatment.
Serum concentrations of sICAM-1, sVCAM-1, sE-selectin and sL-selectin in CHB patients were significantly higher compared to the control group before treatment (P < 0.00001, respectively). In CHB patients responding to the PEG IFN-α-2a treatment, serum levels of sICAM-1, sVCAM-1, sE-selectin and sL-selectin were higher than those in non-responders before treatment (PI = 0.001, PV = 0.002, PE = 0.02, PL = 0.004). The levels of sICAM-1, sVCAM-1, sE-selectin and sL-selectin decreased in virological responders of treatment at 12 and 24 weeks (PI = 0.0001, PV = 0.00004, PE = 0.002, PL = 0.0004; PI = 0.00007, PV = 0.00001, PE = 0.0003, PL = 0.00003), while no obvious changes were observed in non-responders (P > 0.05, respectively).
Results obtained indicated increased levels of sICAM-1, sVCAM-1, sE-selectin and sL-selectin could be related to virological response to PEG IFN-α-2a treatment in CHB patients, and have a prognostic effect on virological response.